A5024958150- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Systemic Sclerosis and Related Diseases
- Spondyloarthritis Studies and Treatments
- Ocular Diseases and Behçet’s Syndrome
- Monoclonal and Polyclonal Antibodies Research
- Chronic Lymphocytic Leukemia Research
- Inflammatory Myopathies and Dermatomyositis
- T-cell and B-cell Immunology
- Vasculitis and related conditions
- Peripheral Neuropathies and Disorders
- Immune Cell Function and Interaction
- Osteoarthritis Treatment and Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Gout, Hyperuricemia, Uric Acid
- Psoriasis: Treatment and Pathogenesis
- Tuberculosis Research and Epidemiology
- Hepatitis C virus research
- Autoimmune Bullous Skin Diseases
- Infectious Diseases and Tuberculosis
- Mast cells and histamine
- Otitis Media and Relapsing Polychondritis
- Eosinophilic Disorders and Syndromes
- Biosimilars and Bioanalytical Methods
Seoul National University
2016-2025
Seoul National University Hospital
2015-2024
New Generation University College
2008-2022
National University College
2008-2022
Seoul National University Bundang Hospital
2018-2022
Center for Rheumatology
2015-2022
Namseoul University
2019-2020
Boramae Medical Center
2020
University of Alabama at Birmingham
2020
Chong Kun Dang Bio (South Korea)
2020
Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that being investigated for the treatment of rheumatoid arthritis.In this 12-month, phase 3 trial, 717 patients who were receiving stable doses methotrexate randomly assigned to 5 mg tofacitinib twice daily, 10 40 adalimumab once every 2 weeks, or placebo. At month 3, in placebo group did not have 20% reduction from baseline number swollen and tender joints switched blinded fashion either daily; at 6, all still fashion. The...
Methotrexate is the most frequently used first-line antirheumatic drug. We report findings of a phase 3 study monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared methotrexate in patients rheumatoid arthritis who had not previously received or therapeutic doses methotrexate.We randomly assigned 958 to receive 5 mg 10 tofacitinib twice daily at dose that was incrementally increased 20 per week over 8 weeks; 956 The coprimary end points month 6 were mean change from...
To compare the efficacy, safety, and tolerability of 5 doses oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for treatment active rheumatoid arthritis (RA) in patients an inadequate response to disease-modifying antirheumatic drugs.In this 24-week, double-blind, phase IIb study, RA (n = 384) were randomized receive placebo, at 1, 3, 5, 10, 15 mg administered orally twice a day, 40 injected subcutaneously every 2 weeks (total 6 injections) followed by day 12 weeks. The...
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report integrated safety summary tofacitinib from two phase I, nine II, six III and long-term extension studies in adult patients with active RA.Data were pooled all tofacitinib-treated (data cut-off: 31 March 2015). Incidence rates (IRs; event/100 patient-years) 95% CIs are reported adverse events (AEs) interest.6194 received a total 19 406 patient-years' exposure; median exposure was 3.4...
To compare efficacy and safety of sarilumab monotherapy with adalimumab in patients active rheumatoid arthritis (RA) who should not continue treatment methotrexate (MTX) due to intolerance or inadequate response.MONARCH was a randomised, active-controlled, double-blind, double-dummy, phase III superiority trial. Patients received (200 mg every 2 weeks (q2w)) (40 q2w) for 24 weeks. The primary end point change from baseline 28-joint disease activity score using erythrocyte sedimentation rate...
To determine whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza in patients with rheumatoid arthritis (RA).In this prospective randomised parallel-group multicentre study, RA on stable dose MTX were randomly assigned at ratio 1:1 to continue or hold for 2 weeks 2016-2017 quadrivalent vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria. The primary outcome was frequency satisfactory response, defined as greater than equal...
Objective To evaluate tofacitinib's effect upon pneumococcal and influenza vaccine immunogenicity. Methods We conducted two studies in patients with rheumatoid arthritis using the 23-valent polysaccharide (PPSV-23) 2011–2012 trivalent vaccine. In study A, tofacitinib-naive were randomised to tofacitinib 10 mg twice daily or placebo, stratified by background methotrexate vaccinated 4 weeks later. B, already receiving (with without methotrexate) into groups: those continuing (‘continuous’)...
Objective To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) prior inadequate response to or intolerance 1 2 tumor necrosis factor inhibitors ( TNF i). Methods In this phase III randomized, double‐blind, placebo‐controlled trial, adult an i established diagnosis SpA (according Assessment SpondyloArthritis international Society [ ASAS ] criteria for SpA, sacroiliitis defined according modified New York ≥1 feature SpA) were...
Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report largest integrated safety analysis tofacitinib, as March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. Methods Data were pooled RA who received ≥1 tofacitinib dose. Incidence rates (IRs; events/100 patient-years [PY]; 95% CIs) first-time occurrences obtained adverse events (AEs) interest. Results 7061 (total...
Abstract Introduction Adiponectin has been implicated in the pathogenesis of osteoarthritis (OA). We studied effects adiponectin on OA cartilage homeostasis. Methods Immunohistochemical analysis was performed to evaluate differential expression receptors (AdipoRs) nonlesional and lesional areas cartilage. Cartilage chondrocytes from knee joints primary patients were cultured presence (0~30 μg/ml). The levels total nitric oxide (NO), matrix metalloproteinase (MMP)-1, -3, -13, tissue inhibitor...
To investigate whether temporary discontinuation of methotrexate (MTX) improves the efficacy seasonal influenza vaccination in patients with rheumatoid arthritis (RA).In this prospective randomised parallel-group trial, RA taking stable dose MTX were randomly assigned at a ratio 1:1:1:1 to continue (group 1), suspend for 4 weeks before 2), 2 and after 3) or 4). All participants vaccinated trivalent vaccine containing H1N1, H3N2 B-Yamagata. The primary outcome was frequency satisfactory...
Amino acids (AAs) are necessary nutrients which act not only as building blocks in protein synthesis, but also crucial anabolic cellular signaling pathways. It has been demonstrated that SLC7A5 is a critical transporter mediates uptake of several essential amino (EAAs) highly proliferative tumors and activated T cells. However, the dynamics relevance activity monocytes/macrophages still poorly understood. We provide evidence SLC7A5-mediated leucine influx contributes to proinflammatory...
Exosomes are involved in intercellular communication. The aim of this study was to investigate whether circulating exosomes effectively contribute the inflammatory response systemic lupus erythematosus (SLE).Exosomes were purified from SLE patients and healthy controls (HCs). Healthy peripheral blood mononuclear cells (PBMCs) stimulated with isolated HCs presence or absence Toll-like receptor (TLR) inhibitors. Production interferon (IFN)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-1β,...
This phase 3 study was undertaken to investigate the efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in patients with diffuse cutaneous systemic sclerosis (dcSSc).A multinational double-blind conducted 365 dcSSc who were randomized dosed 1:1:1 lenabasum 20 mg, 5 or placebo, each twice daily added background treatments, including immunosuppressive therapies (IST).The primary end point, American College Rheumatology combined response index (CRISS) at week 52 for mg day...
Abstract Objective To identify systemic sclerosis (SSc) susceptibility loci via a genome‐wide association study. Methods A study was performed in 137 patients with SSc and 564 controls from Korea using the Affymetrix Human SNP Array 5.0. After fine‐mapping studies, results were replicated 1,107 2,747 US Caucasian population. Results The single‐nucleotide polymorphisms (SNPs) (rs3128930, rs7763822, rs7764491, rs3117230, rs3128965) of HLA–DPB1 DPB2 on chromosome 6 formed distinctive peak log P...
Recent studies have suggested that neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein-to-albumin (CAR) are emerging markers of disease activity prognosis in patients with chronic inflammatory diseases, cardiovascular or malignancies. Therefore, we investigated the clinical significance prognostic value NLR CAR adult polymyositis dermatomyositis. The medical records 197 newly diagnosed polymyositis/dermatomyositis between August 2003 November 2016 were retrospectively reviewed....
Elevated interleukin (IL)-6 occurs in patients with active rheumatoid arthritis (RA), which has been shown to lead a decrease cytochrome P450 (CYP) enzyme activity and alterations drug concentrations metabolized by CYP. IL-6 signaling blockade receptor (IL-6R) antagonists may reverse this effect of restore CYP activity. This study evaluated the pharmacokinetic profile simvastatin (a CYP3A4 substrate) before 1 week after single dose sarilumab human monoclonal antibody [mAb] blocking IL-6Rα)...
Objective. To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes (PROs) in patients with moderate to severe RA and inadequate responses MTX. Methods. In this 12-month, phase 3, randomized controlled trial (ORAL Standard), (n = 717) receiving background MTX were 5 10 mg twice daily (BID), 40 once every 2 weeks placebo. PROs included HAQ-Disability Index, Patient Global Assessment Arthritis, Arthritis Pain, health-related quality life (Short Form-36 [SF-36]), fatigue...